While current guidelines set the target MRD sensitivity for multiple myeloma at ten times greater than this threshold and MRD status is commonly reported at 10−5 sensitivity, both next generation sequencing and NGF have reproducibly achieved 1–2 × 10−6 sensitivity.8 The Euroflow consortium established that MRD NGF assays should be performed at 2 × 10−6 analytical sensitivity (LOD) and 5 × 10−6 functional sensitivity (LLOQ).1 In our study, we calculated an assay performance of 1.9 × 10−6 LOD and 5.7 × 10−6 LLOQ matching Euroflow assay performance characteristics. This evidence concerns the gene NGF and plasma cell myeloma.